All News

podcast logo

RheumNow Podcast – Rheum Lives Matter (8.28.20)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week. Of mice and men in cartilage, the efficacy of JAK inhibitors in patients who are having skin problems, nrAxSpa has its own diagnostic code, metformin, talking about Back Talk, plus so much more.

Read Article
podcast logo

RheumNow Podcast - Top 13 Rheumatology Centers (7-31-20)

Jack Cush, MD

Dr. Jack Cush reviews the news and TOP 13 list of Best Rheumatology Hospitals.

Read Article
podcast logo

RheumNow Podcast – COVID-19 Responds to Steroids (7.24.20)

Jack Cush, MD

Dr. Jack Cush reviews the News and Journal Reports from the past week on RheumNow.com.

Read Article
FINAL 2020 Podcast Graphic

RheumNow Podcast – LTF – Listen to Fauci (7.17.20)

Jack Cush, MD

Dr. Jack Cush reviews the news, tweets and journal articles from the past week on RheumNow. Let's dig into this week's 14 highlights.

Read Article
heart.EKG_.CVD_.jpg

CV Risks Raised in Myopathies

Jack Cush, MD

Patients with the idiopathic inflammatory myopathies (IIMs) dermatomyositis and polymyositis are at increased risk for cardiovascular events, with risks similar to what has been documented for rheumatoid arthritis (RA), during the first 5 years after diagnosis, U.K. researchers reported.

Read Article
janefingr.JPG

Lenabasum Encouraging in Systemic Sclerosis

RheumNow

The oral cannabinoid receptor type 2 (CB2) agonist lenabasum showed promising results for systemic sclerosis (SSc) in a phase II study.

Read Article
RN.podcast.resized.jpg

RheumNow Podcast- 2019 EULAR RA Guidelines (1.31.20)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
myositis.jpg

Treatment of Statin-induced anti-HMGCR myopathy

Jack Cush, MD

Statin-induced myositis, often with anti-HMGCR autoantibodies can be difficult to manage, Arthritis Research & Therapy yhas published the experience of 55 patient with HMGCR myopathy, demonstrating that while steroid management may be reasonable in select patients, the use of tr

Read Article
ACRmtg.jpg (keep)

ACR 2018 - Day 3 Report

RheumNow

Highlights from Tuesday, day 3 of the ACR Annual meeting in Chicago, included the PEXIVAS Study, ACR Reproductive Health Draft Guidelines, and a Proof of concept study

Read Article
RN.podcast.resized.jpg

RheumNow Podcast – Women Take Over Rheumatology (10.4.19)

Jack Cush, MD

Dr. Jack Cush reviews the News and Journal Reports from this week on RheumNow.com.

Read Article
arthritis.RA_.Xray_.hands_.jpg (keep)

Persistent Inflammatory Arthritis After Immune Checkpoint Inhibitors

Jack Cush, MD

Braaten and colleagues from Johns Hopkins School of Medicine have reported their experience with chronic inflammatory arthritis induced by immune checkpoint inhibitor therapies, showing that in some, inflammatory arthritis persists after the immunotherapy has been discontinued.

Read Article
Among a 112 patient inflammatory myositis cohort, inclusion body myositis was rare (4 pts) - they tend to be older (67 yrs), male predominance, lower CK (1326-1968), less severe weakness 3.75/5) and poor response to immunosuppressives. https://t.co/VxLOAjstWo

Links:

Dr. John Cush RheumNow ( View Tweet)

ILD studied in 679 inflammatory idiopathic myositis (IIM) pts; 508 had ILD (found in 93% amyopathic DM, 74% DM & 55% PM). Prevalence of of ILD was higher with antisynthetase Ab + and MDA-5 Ab +. Mortality higher in MDA5+ASA--IM-ILD group (33% vs 12=17%) https://t.co/ATz3wYmFuf

Links:

Dr. John Cush RheumNow ( View Tweet)

Hong Kong study Myositis-specific autoantibodies in 201 pts with idiopathic inflammatory myopathies (IIM) shows MDA-5 (14%), TIFF-1γ (14%), Jo-(12.4%). MDA5 seen w/ DM, digital ulcers, amyopathy, ILD. TIF1γ was associ w/ refractory rash and cancer https://t.co/3E365F5SON

Links:

Dr. John Cush RheumNow ( View Tweet)

Fracture risk & prevalence of osteoporosis is elevated in patients with idiopathic inflammatory myopathies: cross-sectional comparison of 52 myositis and 43 RA pts. OP Prevalence higher in the myositis group (13.5% v 7%) but equal fracture risk (68 v 75%) https://t.co/XT6O9HoqdH

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is Up! Listen to Fauci! Watch it here>> https://t.co/dHq3fP85Ip or Listen to the Podcast>> https://t.co/LdHO7fKUCp

Links:

Dr. John Cush RheumNow ( View Tweet)

Retrospective study of 603 myositis (IIM), 4047 RA and 4061 controls shows IIM has higher risk of CV events (HR 1.38) and MI [HR 1.61] but not CVA [HR 0.92]. The CV risk in IIM was equal to that in RA [HR 1.01]. IIM CV risk only present 1st 5 years https://t.co/EyD3GHv2YY

Links:

Dr. John Cush RheumNow ( View Tweet)

Systematic review of DYSPHAGIA in inflammatory myositis finds it may be an initial or sole symptom. Prevalence in IIM was 36% and higher 56% inclusion body myositis, cancer or NXP2 -associated myositis. Dysphagia may be complicated by aspiration pneumonia https://t.co/wDg3tWaooP

Links:

Dr. John Cush RheumNow ( View Tweet)

#EULAR2020 #op0169 US claims database analysis reveals that gout and DM make for a dangerous combination: significantly higher risk of amputations in pts with gout+DM at 0.77% as oppose to DM w/out gout 0.461% & gout w/out DM 0.162% @RheumNow

Olga Petryna DrPetryna ( View Tweet)

#EULAR2020 Recc for irAEs w/ICI: 1. GC's ok, goal<10 mg/d, any csDMARD, bDMARD (TNFi/IL-6),🚫ABT xcept life-threatening myositis 2. Myositis beware bulbar signs: dysphagia, dysarthria, dysphonia: stop ICIs,⬆️GC, IVIG/PE 3. Don't test autoAbs b/f ICI Rx https://t.co/P5jDgnjK94

Links:

k dao KDAO2011 ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×